October 16, 2017 02:12 AM EDTUpdated December 20, 09:13 PM

EMA counters the academics who criticized the cancer drug approval process

Zachary Brennan

Senior Editor

As more cancer drugs are approved and prices continue to rise, questions have circulated on whether these drugs are extending patient survival or improving quality …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EMA counters the academics who criticized the cancer drug approval process

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

EMA coun­ters the aca­d­e­mics who crit­i­cized the can­cer drug ap­proval process

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

EMA counters the academics who criticized the cancer drug approval process

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings